Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
| Autor: | Natalia Rodrigues Mantuano, Heinz Läubli, Alfred Zippelius, Marina Natoli |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
lymphocytes
0301 basic medicine Cancer Research T cell medicine.medical_treatment Immunology Carbohydrates Review Immunomodulation 03 medical and health sciences 0302 clinical medicine Immune system Cancer immunotherapy Antigen antigens Lectins Neoplasms medicine tumor-associated Humans Immunology and Allergy Receptor RC254-282 Pharmacology biology Neoplasms. Tumors. Oncology. Including cancer and carcinogens SIGLEC tumor-infiltrating Immune checkpoint 030104 developmental biology medicine.anatomical_structure Oncology carbohydrate 030220 oncology & carcinogenesis Cancer research biology.protein Molecular Medicine Immunotherapy Antibody |
| Zdroj: | Journal for Immunotherapy of Cancer Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020) |
| ISSN: | 2051-1426 |
| Popis: | During oncogenesis, tumor cells present specific carbohydrate chains that are new targets for cancer immunotherapy. Whereas these tumor-associated carbohydrates (TACA) can be targeted with antibodies and vaccination approaches, TACA including sialic acid-containing glycans are able to inhibit anticancer immune responses by engagement of immune receptors on leukocytes. A family of immune-modulating receptors are sialic acid-binding Siglec receptors that have been recently described to inhibit antitumor activity mediated by myeloid cells, natural killer cells and T cells. Other TACA-binding receptors including selectins have been linked to cancer progression. Recent studies have shown that glycan-lectin interactions can be targeted to improve cancer immunotherapy. For example, interactions between the immune checkpoint T cell immunoglobulin and mucin-domain containing-3 and the lectin galectin-9 are targeted in clinical trials. In addition, an antibody against the lectin Siglec-15 is being tested in an early clinical trial. In this review, we summarize the previous and current efforts to target TACA and to inhibit inhibitory immune receptors binding to TACA including the Siglec-sialoglycan axis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|